MedPath

ROSWELL PARK CANCER INSTITUTE

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Phase 1
Suspended
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Other: Best Practice
Biological: Recombinant Interferon Alfa-2b
First Posted Date
2020-05-07
Last Posted Date
2023-03-06
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
64
Registration Number
NCT04379518
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Consumer Assessment of Tobacco Flavor and Odor

Active, not recruiting
Conditions
Current Vaper
Healthy Subject
Interventions
Behavioral: Behavioral Intervention
Other: Questionnaire Administration
First Posted Date
2020-04-24
Last Posted Date
2025-02-07
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
29
Registration Number
NCT04358315
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Phase 2
Recruiting
Conditions
Metastatic Triple-Negative Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Malignant Neoplasm in the Brain
Prognostic Stage IV Breast Cancer AJCC v8
Interventions
First Posted Date
2020-04-16
Last Posted Date
2025-07-02
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
23
Registration Number
NCT04348747
Locations
πŸ‡ΊπŸ‡Έ

Moffitt Cancer Center, Tampa, Florida, United States

πŸ‡ΊπŸ‡Έ

Moffitt Cancer Center, Tampa, Florida, United States

πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

and more 3 locations

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Early Phase 1
Recruiting
Conditions
Stage IIA Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Chronic Obstructive Pulmonary Disease
Pneumonia
Stage II Lung Cancer AJCC v8
Lung Non-Small Cell Carcinoma
Stage IIB Lung Cancer AJCC v8
Stage IB Lung Cancer AJCC v8
Interventions
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
First Posted Date
2020-03-06
Last Posted Date
2025-05-02
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
60
Registration Number
NCT04298606
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice

Not Applicable
Completed
Conditions
Metastatic Breast Carcinoma
Breast Carcinoma
Recurrent Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Other: Informational Intervention
Other: Quality-of-Life Assessment
Other: Survey Administration
First Posted Date
2020-03-05
Last Posted Date
2023-04-10
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
174
Registration Number
NCT04297384
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Episodic Future Thinking and Future Thinking Priming for Smoking Cessation

Not Applicable
Terminated
Conditions
Tobacco-Related Carcinoma
Interventions
Behavioral: Behavioral Intervention
Other: Informational Intervention
Other: Telephone-Based Intervention
First Posted Date
2020-03-05
Last Posted Date
2024-02-08
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
26
Registration Number
NCT04297332
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Web-Based Lifestyle Intervention for the Improvement of Health in African American Cancer Survivors

Not Applicable
Withdrawn
Conditions
Cancer Survivor
Interventions
Behavioral: Lifestyle Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
First Posted Date
2020-03-02
Last Posted Date
2023-04-27
Lead Sponsor
Roswell Park Cancer Institute
Registration Number
NCT04290962
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

Phase 2
Recruiting
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Secondary Acute Myeloid Leukemia
Therapy-Related Acute Myeloid Leukemia
Interventions
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
First Posted Date
2020-02-13
Last Posted Date
2025-01-31
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
46
Registration Number
NCT04269213
Locations
πŸ‡ΊπŸ‡Έ

University of Nebraska Medical Center, Omaha, Nebraska, United States

πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

πŸ‡ΊπŸ‡Έ

SUNY Upstate Medical Center, Syracuse, New York, United States

and more 1 locations

Pharmacokinetics, Subjective Effects, and Abuse Liability of Nicotine Salt-Based Vaping Products With Tobacco or Unflavored E-liquids, SALTVAPE Study

Not Applicable
Active, not recruiting
Conditions
Nicotine Dependence
Interventions
Device: Vaporizer Device
First Posted Date
2020-01-18
Last Posted Date
2024-07-15
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
20
Registration Number
NCT04231539
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

Phase 1
Completed
Conditions
Refractory Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Interventions
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
First Posted Date
2019-12-20
Last Posted Date
2024-11-01
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
24
Registration Number
NCT04207190
Locations
πŸ‡ΊπŸ‡Έ

University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States

πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Β© Copyright 2025. All Rights Reserved by MedPath